We hypothesized that engineering TCZ-conjugated nanoparticles could achieve dual therapeutic objectives: (1) active tumor targeting through IL-6R binding, and (2) the simultaneous blockade of IL-6-driven chemoresistance pathways. Here, IL6 is linked to neoplasm.